Anti-CD11b monoclonal antibody LM2
Alternative Names: LM2; LM2 antibodyLatest Information Update: 24 Oct 2021
At a glance
- Originator Ohio State University
- Class Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD11b antigen antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 11 Nov 2003 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 14 Jul 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)
- 13 Dec 1995 Preclinical development for Transplant rejection in USA (Unknown route)